呼吸机相关性肺炎的痰培养细菌分布和细菌耐药性分析

目的:探讨呼吸机相关性肺炎痰培养的泛耐药鲍曼不动杆菌的分布情况,分析泛耐药鲍曼不动杆菌的耐药性与危险因素。方法:选择2016年1月到2016年12月在我院进行机械通气的患者3826例作为研究对象,其中发生泛耐药鲍曼不动杆菌呼吸机相关性肺炎98例为观察组,同期按照2:1的比例选择非泛耐药鲍曼不动杆菌呼吸机相关性肺炎患者49例作为对照组,两组都进行细菌耐药性分析,同时调查患者的临床资料,分析呼吸机相关性肺炎患者中泛耐药鲍曼不动杆菌感染发生的危险因素。结果:观察组对于头孢噻肟、哌拉西林、亚胺培南、庆大霉素、左氧氟沙星、四环素、头孢他啶都高度耐药;除哌拉西林、多粘菌素外,对照组对抗菌药物的耐药率均明显低于观察组(P0.05)。单因素分析结果显示合并糖尿病、机械通气时间、APACHEⅡ评分、GCS评分、深静脉置管等因素与呼吸机相关性肺炎患者中泛耐药鲍曼不动杆菌感染显著相关(P0.05);非条件Logistic回归分析结果显示糖尿病、机械通气时间、APACHEⅡ评分、GCS评分导致呼吸机相关性肺炎患者中泛耐药鲍曼不动杆菌感染的独立危险因素(P0.05)。结论:呼吸机相关性肺炎患者中泛耐药鲍曼不动杆菌感染比较常见,对绝大多数抗菌药物有耐药性,糖尿病、机械通气时间、APACHEⅡ评分、GCS评分为主要的危险因素。     

Immunogenicity of recombinant human erythropoietin in Korea: a two-year cross-sectional study

Immunogenicity of erythropoietin (EPO) is related with pure red cell aplasia (PRCA). We sought to determine the prevalence of antibody (Ab)-mediated PRCA in Korea and threshold diagnostic criteria by dual parameters: Ab titer and neutralizing activity. This study was a multi-center, cross-sectional study for two years. In the first year study (1 YS), 209 samples suspected to be EPO resistance were collected. In the second year study (2 YS), all the patients who consented to participate (N = 946) were enrolled. In 1 YS, we found three and six serum samples that were positive and borderline for anti-EPO Abs, respectively. The first three patients had neutralizing activity (NT) and were diagnosed as PRCA. In 2 YS, seven patients were anti-EPO positives and six had borderline levels. Among them, one patient with NT was diagnosed as PRCA and one with NT as aplastic anemia. The prevalence of PRCA was 0.106%. The correlation analysis of the 22 patients who had anti-EPO Ab showed that dual crossed cut-off lines (anti-EPO Ab titer ≥ 40 ng/ml, % NT ≥ 25%) were able to clearly isolate red cell aplasia. We suggest novel diagnostic criteria for diagnosis and prediction of Ab-mediated PRCA with data from both Ab titer assays and NT bioassays.     

Development and Evaluation of a Simple Latex Agglutination Test for Diagnosis of Tuberculosis

A simple latex agglutination test (SLAT) based on modifications of existing serodiagnostic techniques, in which commercially available reagents are used, was developed for detection of antibodies against Mycobacterium tuberculosis. Tests performed on 553 serum samples from 316 individuals, including 117 bacteriologically confirmed active tuberculosis patients, showed 80% positive titers. Sera from 12 patients with arrested tuberculosis showed 91% positive titers. Nonspecific reactions were noted in 5% of 160 serums from selected normal individuals and patients with diseases other than tuberculosis. The antibodies detected by the SLAT method were found to be relatively stable when exposed to low temperatures, whereas high temperatures reduced the antibody titer considerably. Disodium ethylenediaminetetraacetic acid inactivation of serum complement was found to be satisfactory. No variation of tuberculosis antibody titer was noted in tests on multiple specimens from patients whose conditions were stabilized. However, considerable fluctuation was encountered in antibody titers obtained on recently detected individuals. Data obtained in this study indicate that the modified procedures of the SLAT method could replace the tuberculin skin test for simple screening of tuberculosis in adults.     

ABO血型正反定型及交叉配血实验在外科病人手术输血中应用

目的:探讨ABO血型正反定型及交叉配血实验在外科手术患者输血中的应用效果及影响因素。方法:选取我院自2017年2月-2019年2月收治的80例行ABO正反定型与交叉配血治疗的外科手术患者,记录ABO反定型与交叉配血不合的标本,使用2-Me处理被患者自身冷抗体凝集的红细胞,同时使用微柱凝胶法、凝聚胺法对血型不规则抗体以及特异性进行筛选和鉴定。分析ABO血型反定型不符合以及交叉配血不合的影响因素。结果:对正反定型完全无凝集反应的80例血清标本进行交叉配血实验,其中8例存在凝集反应,配血不合情况;导致外科手术患者输血中ABO血型反定型不符交叉配血不合的主要因素包括自身冷抗体、血型抗原性减弱、血型不规则抗体以及血型抗体效价减弱等。结论:ABO血型正反定型及交叉配血治疗中的患者中,大部分配血一致,少数的交叉配血不合,主要与自身冷抗体、血型抗原性减弱、血型不规则抗体以及血型抗体效价减弱等因素相关。     

Continuous Infusion of Piperacillin/Tazobactam in Septic Critically Ill Patients—A Multicenter Propensity Matched Analysis

The clinical efficacy of continuous infusion of piperacillin/tazobactam in critically ill patients with microbiologically documented infections is currently unknown. We conducted a retrospective multicenter cohort study in 7 Portuguese intensive care units (ICU). We included 569 critically ill adult patients with a documented infection and treated with piperacillin/tazobactam admitted to one of the participating ICU between 2006 and 2010. We successfully matched 173 pairs of patients according to whether they received continuous or conventional intermittent dosing of piperacillin/tazobactam, using a propensity score to adjust for confounding variables. The majority of patients received 16g/day of piperacillin plus 2g/day of tazobactam. The 28-day mortality rate was 28.3% in both groups (p = 1.0). The ICU and in-hospital mortality were also similar either in those receiving continuous infusion or intermittent dosing (23.7% vs. 20.2%, p = 0.512 and 41.6% vs. 40.5%, p = 0.913, respectively). In the subgroup of patients with a Simplified Acute Physiology Score (SAPS) II>42, the 28-day mortality rate was lower in the continuous infusion group (31.4% vs. 35.2%) although not reaching significance (p = 0.66). We concluded that the clinical efficacy of piperacillin/tazobactam in this heterogeneous group of critically ill patients infected with susceptible bacteria was independent of its mode of administration, either continuous infusion or intermittent dosing.     

康柏西普联合全视网膜光凝治疗糖尿病黄斑水肿的疗效分析

目的:研究康柏西普联合全视网膜光凝(panretinal photocoagulation,PRP)治疗糖尿病黄斑水肿(diabetic macular edema, DME)的疗效及安全性。方法:回顾性分析2016年4月到2018年4月本院接诊的DME患者238例,按照治疗方式的不同将其分成观察组及对照组。对照组采用PRP治疗,观察组则采用抗血管内皮生长因子(vascular endothelial growth factor, VEGF)药物康柏西普联合PRP实施治疗。比较两组患者治疗后的临床效果、手术前后视力和黄斑中心凹厚度的变化及预后情况。结果:治疗后,观察组的治疗效率为94.96%,较对照组(84.87%)显著升高(P0.05)。观察组术后视力明显高于手术前(P0.05),且显著高于对照组(P0.05);观察组术后黄斑中心凹厚度明显小于术前(P0.05),且显著小于对照组。观察组并发症发生率(3.36%)明显低于对照组(10.92%,P0.05)。结论:康柏西普联合PRP治疗DME患者的效果显著优于单用PRP治疗,且安全性更高。     

Serological Study of Bartonella henselae in Cat Scratch Disease in Japan

It has become clear that Bartonella henselae is a common cause of cat scratch disease (CSD). The indirect fluorescence antibody (IFA) test for detection of IgG and IgM antibodies to B. henselae concerning CSD showed that 5 (50%) of 10 patients with CSD had a serum IgG antibody titer of 1:128 or more and that 2 (20%) patients had a serum IgM antibody titer of 1:20 or more. One of 7 asymptomatic members of patients' families (14%) had IgG antibody to B. henselae at a titer of 1:256. IgM antibody to B. henselae was not detected in sera from the patients' families. Both IgG and IgM antibodies to B. henselae were not detected in sera from the healthy control group. These data suggest that B. henselae may be a cause of CSD in Japan.     

支气管扩张合并支气管哮喘患者支气管肺泡灌洗液病原菌培养及药敏状况研究

目的:对支气管扩张合并支气管哮喘患者支气管肺泡灌洗液病原菌培养及药敏状况展开分析,实现多药耐药医院感染的有效预防与控制。方法:随机选取2010年9月~2013年8月期间收治的50例支气管扩张症合并支气管哮喘患者,对50例患者支气管肺泡灌洗液标本进行病原学检测及药敏试验,并对临床感染资料及病原菌耐药性进行统计学分析。结果:50例支气管扩张症合并支气管哮喘患者支气管肺泡灌洗液培养阳性率为30例,60.0%,共分离出48株细菌。其中,革兰阳性球菌5株,占分离菌的10.4%;革兰阴性杆菌41株,占分离菌的85.4%;真菌2株,占分离菌的4.2%。41株革兰阴性杆菌对抗菌药物的耐药性分别为:复方新诺明73.1%,阿米卡星22.0%,环丙沙星14.6%,头孢曲松48.8%,头孢噻肟41.5%,头孢哌酮19.5%,头孢他啶20.7%,头孢他啶/舒巴坦12.1%,头孢吡肟22.0%,庆大霉素17.1%,阿莫西林/克拉维酸41.5%,哌拉西林/他唑巴坦19.5%。结论:铜绿假单胞菌是支气管扩张合并哮喘患者感染中的常见病原菌,医务人员要结合病原菌高耐药率、高分离阳性率的特征,合理运用抗菌药物控制传播。     

Optimum duration of antithyroid drug treatment determined by assay of thyroid stimulating antibody in patients with Graves' disease.

OBJECTIVE--To determine the optimal duration of antithyroid drug treatment by monitoring serum thyroid stimulating antibody values in patients with Graves'' disease. DESIGN--Prospective longitudinal trial of patients with Graves'' disease followed up for 24 months after withdrawal of treatment. SETTING--Tertiary referral centre. PATIENTS--A total of 64 consecutive patients with untreated Graves'' disease, eight of whom were subsequently excluded. Fifty six patients completed the study. INTERVENTIONS--All patients were treated initially with carbimazole 40 mg, then with decreasing doses that maintained a euthyroid state. Treatment was scheduled to continue for 18 months but was withdrawn earlier if serum thyroid stimulating antibody became undetectable. END POINT--Serum values of thyroid stimulating antibody (assayed by stimulation of human thyroid cells in vitro) and thyroid hormones and thyroid state every three months during treatment and afterwards every six months for 24 months. MEASUREMENTS AND MAIN RESULTS--In 44 patients serum thyroid stimulating antibody became undetectable during treatment and treatment was withdrawn (median duration of treatment nine months, range 3-18 months). In 12 patients the antibody could be detected during 18 months of treatment. Among the first group of 44 patients initial values of the antibody before treatment were significantly lower than in the second group of 12 patients (median 225% (range 138-1236%) v 570% (250-1480%), p less than 0.001); the incidence of relapse was also lower (41% v 92%, p less than 0.001); and among those who did relapse the disease free interval after treatment was longer (median 12 months v 1 month, p less than 0.001). Moreover, the initial median serum values of thyroid stimulating antibodies were not related to the occurrence of relapse or remission as these did not differ between patients who did and did not have a relapse (median 267% (range 139-1480%) v 220% (range 138-1236%). CONCLUSION--Monitoring of serum thyroid stimulating antibody was a good guide to the duration of treatment as it allowed the treatment period to be considerably shortened in a large group of patients with no loss of efficiency.     

Prevalence of Serum IgG Antibodies to Cystic Echinococcus Antigen among Patients in an Uzbekistan Emergency Hospital

Cystic echinococcosis (CE) is one of the most widespread zoonotic helminthiases, which can last an asymptomatic infection for several years. The purpose of this study was to demonstrate serum antibody prevalence of CE among asymptomatic people in Uzbekistan using ELISA. A total of 2,547 serum samples were collected, 66 from confirmed CE patients and 2,481 of patients with other diseases than CE at a hospital in Tashkent, Uzbekistan. The serum samples were screened for CE specific IgG antibodies by ELISA using cystic fluid antigen obtained from sheep. The serum antibody positive rate was 89.4% (59/66) in CE and 3.6% (89/2,481) in other disease patients. The present ELISA recognized 89.4% sensitivity and 96.4% specificity. The ELISA absorbance of positive samples was distributed 0.271-0.971 for CE and 0.273-0.887 for other disease patients. The other disease patients with high absorbance over 0.3 were 50 (2.0%) who were presumed to be active CE patients. The patients in their 40s showed the highest positive rate of 5.2% (P=0.181), and women were 4.4% while men were 3.1% positive (P=0.136). The data confirmed that there are many asymptomatic patients of CE in Tashkent. It is indicated that CE is an endemic disease of public health importance in Uzbekistan.     

口腔雾化药物吸入联合小儿双金清热口服液治疗疱疹性口炎的临床疗效

目的:研究口腔雾化药物吸入联合小儿双金清热口服液治疗疱疹性口炎的临床疗效。方法:选择2012年5月至2014年5月在我院接受治疗的疱疹性口炎患者122例实施研究。根据数字法随机分成观察组及对照组各61例,观察组给予口腔雾化药物吸入以及小儿双金清热口服液进行治疗,对照组单纯给予小儿双金清热口服液进行治疗,对比两组治疗后的疗效、相关康复指标以及治疗后的不良反应。结果:观察组的总有效率是98.36%,显著高于对照组的88.52%,差异有统计学意义(P0.05)。观察组的热退时间和疱疹消退时间以及康复时间均分别显著少于对照组,差异均有统计学意义(均P0.05)。观察组治疗后的总不良反应发生率与对照组相比,差异无统计学意义(P0.05)。结论:利用口腔雾化药物吸入联合小儿双金清热口服液对疱疹性口炎患儿进行治疗,效果较好,安全性更高,值得在临床上推广应用。     

Indwelling catheter infection

A “catheter team”, consisting of two hospital assistants specially trained to catheterize male patients, inserted indwelling catheters in 435 men over a two-year period. The infection rate was 33%; in the 200 patients not treated with antimicrobial drugs (study group) the rate was 37%, while in the 235 patients who were so treated (antibacterial group) the infection rate was 29%. Fifty percent of patients not treated were infected after 6.3 days, whereas in patients on antibacterial therapy a 50% infection rate was not reached until 14 days after insertion. Therefore, no antibacterial therapy is necessary if it is anticipated that the catheter will be necessary for less than four days. On the other hand, prophylactic antibacterial therapy would delay the onset of infection considerably if catheterization were expected to continue for more than four days. Sulfisoxazole was our drug of choice for prophylactic treatment.     

Contribution of Pseudomonas Aeruginosa strains to infections in patients of specialistic outpatients clinics of the SP ZOZ in Nidzica

The aim of this study was to examine a frequency of isolation and analysis of drug susceptibility o P. aeruginosa strains cultured from clinical specimens obtained from patients treated in specialistic outpatient clinics of the Samodzielny Publiczny Zespó? Opieki Zdrowotnej (SP ZOZ) in Nidzica durin 40 months (01. 09. 2000 - 31. 12. 2003). Ninety six P. aeruginosa strains were cultured out of 829 clinical samples collected from ambulatory patients and processed in the Bacteriological Laboratory of SP ZOZ in Nidzica during over three years. P. aeruginosa strains were isolated from 11.6% of examined specimens. The greatest number of strains (49.0%) were cultured from urine samples obtained from children. Identification of strains was performed using biochemical tests (Becton Dickinson, Emapol, bio-Merieux). Susceptibility of strains to antimicrobial agents was determined with disc diffusion method according to NCCLS recommendations. Special tests were applied to detect extended-spectrum beta-lactamases (ESBL). The most active in vitro against isolated P. aeruginosa strains was a carbapenem - imipenem. All strains were susceptible to this antibiotic. Ciprofloxacin (94.8% of susceptible strains), ceftazidime (89.6%), gentamicin (86.5%), piperacillin (84.4%) and aztreonam (76.0%) were active against the majority of P. aeruginosa strains isolated from ambulatory patients. Six strains (6.25% of all strains) producing extended--spectrum beta--lactamases (ESBL) were detected. It is alarming, that the majority of P. aeruginosa strains from outpatients were cultured out of pediatric samples (61.5%). Because of an increase in resistance and appearance of new mechanisms of resistance to antibiotics/chemotherapeutics in P. aeruginosa strains, it is necessary to monitor a drug susceptibility of these strains causing infections in ambulatory patients.     

Comparative analysis of antibody responses to SARS-CoV-2 in various populations

This paper aimed to analyze antibody responses to SARS-CoV-2 in various populations. Two hundred and six COVID-19 patients, 46 convalescent patients, and 270 healthy population were enrolled. Antibodies against nucleocapsid protein (N) and spike protein''s receptor-binding domain (RBD), and neutralizing antibody were detected. The results demonstrated both anti-N and anti-RBD antibodies could be detected in about 80% of COVID-19 patients and 90% of convalescent patients, while no antibodies could be detected in some convalescents and patients even after 14 days post-onset of symptoms. The level of anti-RBD antibody strongly correlated with the neutralizing activity of sera from these two cohorts. The titer of neutralizing antibody was lower in convalescents than that in active COVID-19 patients. In addition, the titer of neutralizing antibody was less than 1:80 in none of the severe COVID-19 patients, 18.8% in non-severe COVID-19 patients, and 32.6% in convalescents. The study suggests that the level of anti-RBD antibody is closely related to neutralization activity in COVID-19 patients and convalescents. Some SARS-CoV-2-infected cases trigger a weak antiviral immune response, and the level of neutralizing antibody may have a faster decay rate.     

HIV and HTLV-I antibody studies: pregnant women in the 1960s, patients with AIDS, homosexuals, and individuals with tropical spastic paraparesis

To investigate the possible occurrence of human immunodeficiency virus (HIV) or human T-cell lymphotropic virus, type I (HTLV-I) infections in the United States prior to 1979-1981, when acquired immune deficiency syndrome (AIDS) was first recognized, we tested sera from 310 pregnant women who participated in the Collaborative Perinatal Project during the period 1959-1964 for HIV and HTLV-I antibody. These samples included sera from 53 pregnant women who were intravenous drug users. The remainder were from women who had cervical epithelial abnormalities, who developed cervical carcinomas, who had had children with erythroblastosis fetalis, who had had children that developed malignant neoplasms early in life, or normal pregnant women. None of the 310 women had confirmed HIV or HTLV-I antibody. The rate of false-positive reactions with the HIV enzyme-linked immunosorbent assay (ELISA) antibody test in these long-frozen samples was similar to that observed in fresh sera. HIV antibody was detected in homosexual patients with AIDS; HTLV-I antibody was not detected in any of these sera. HTLV-I antibody was detected in 17 of 20 patients with tropical spastic paraparesis (TSP) and in two of seven patients with other neurological diseases diagnosed as transverse myelopathy and multiple sclerosis, and in none of nine normal controls; HIV antibody was not detected in any of these sera patients. Thus, we conclude that there was no serological evidence of infection with HIV or HTLV-I in the pregnant women studied; however, HIV antibody was present in all AIDS patients tested, and HTLV-I antibody was found in the majority of patients with TSP.     

西藏拉萨地区常见致病菌及其耐药性分析

目的研究2009年至2011年西藏拉萨地区主要医院的常见致病菌及其耐药性情况。方法采集拉萨市临床医院细菌感染性疾病临床标本1 200份进行致病菌的分离。采用法国梅里埃-ATB菌种鉴定仪对分离的菌株鉴定到种,参照2010年CLSI推荐方法进行耐药性分析。结果对拉萨地区主要临床医院的感染者标本分离鉴定出332株临床致病菌,其中细菌304株(91.57%),真菌28株(8.43%)。病原细菌分布主要为革兰阳性球菌97株,占29.22%;革兰阴性杆菌200株,占60.24%;其他菌7株,占2.11%。凝固酶阴性葡萄球菌对苯唑西林﹑头孢曲松和环丙沙星的耐药率分别为72%﹑40%和44%。大肠埃希菌对氨苄西林﹑哌拉西林和头孢唑林耐药率分别为83%﹑53%和43%。克雷伯菌属对氨苄西林﹑头孢唑林耐药率分别为86%和58%。铜绿假单胞菌和不动杆菌对亚胺培南的耐药率分别高达20%和19%。结论拉萨地区的细菌感染及其耐药菌株分布较为广泛,该地区应加强常规临床致病菌的耐药性监测以指导临床医师合理使用抗菌药物。     

胆总管结石患者胆汁病原菌分布特点及耐药性分析

目的:探讨胆总管结石患者胆汁病原菌的分布特点以及耐药性的分析。方法:选择2016年6月-2017年6月期间我院收治的胆总管结石合并胆道感染患者160例为研究对象,所有患者均进行逆行内镜胰胆管造影(ERCP)并抽取胆汁标本,进行细菌培养和耐药性实验,评价分析胆汁病原菌的分布特点及耐药性情况。结果:160例患者中有117例(73.13%)检出病原菌,共培养出病原菌130株,其中有13例患者为两种病原菌同时感染。革兰阴性菌有95株(73.08%)、革兰阳性菌有31株(23.85%)、真菌有4株(3.08%)。比例由高到低的前六位病原菌依次为:大肠埃希菌、肺炎克雷伯菌、阴沟肠杆菌、屎肠球菌、铜绿假单胞菌、粪肠球菌。革兰阴性菌对亚胺培南、阿米卡星、美罗培南、他唑巴坦、头孢吡肟等三四代头孢菌素耐药率较低,对头孢曲松、环丙沙星、左氧氟沙星、哌拉西林、氨苄西林等耐药率较高。革兰阳性菌对替拉考宁、万古霉素、利奈唑胺等耐药率较低,对四环素、环丙沙星、左氧氟沙星、克林霉素、氨苄西林等耐药率较高。真菌对酮康唑、伊曲康唑、氟康唑等耐药率较低,对两性霉素B耐药率较高。结论:胆总管结石患者胆汁病原菌主要为革兰阴性菌、其次为革兰阳性菌,各病原菌对各种抗菌药物表现出不同的耐药性,因此在临床治疗时应参考药敏试验结果进行合理选择治疗药物。     

盐酸氨基葡萄糖联合非甾体抗炎药治疗中度膝关节骨关节炎的临床研究

目的:探讨盐酸氨基葡萄糖联合非甾体抗炎药治疗中度膝关节骨关节炎的临床疗效。方法:收集2010年5月至2013年9月我院中度膝关节骨关节炎患者214例,随机分为实验组和对照组各107例,对照组单独给予盐酸氨基葡萄糖治疗,实验组给予盐酸氨基葡萄糖联合非甾体抗炎药治疗,于用药后2、4、8、12周对比两组Lequesne评分、治疗效果和不良反应。结果:两组治疗前Lequesne评分比较差异无统计学意义(P>0.05)。实验组用药后2、4、8、12周Lequesne评分均低于对照组,差异均有统计学意义(P<0.05),且两组Lequesne评分均于用药后2、4周达到最低;用药12周后,两组有效率均有所下降,实验组用药后2、4、8、12周有效率均高于对照组,差异有统计学意义(P<0.05),且两组有效率均于用药后2、4周达到最高;实验组不良反应发生率为6.54%(7/107),显著高于对照组的3.74%(4/107),差异无统计学意义(P>0.05)。结论 :盐酸氨基葡萄糖联合非甾体抗炎药治疗中度膝关节骨关节炎短期疗效较好,长期服用副作用大,临床应推荐2-4周内短期服用。     

斑点叉尾鲖源海豚链球菌Srr蛋白海藻酸钠-壳聚糖口服疫苗的制备及其免疫效果研究

制备海藻酸钠-壳聚糖-海豚链球菌Srr蛋白微球疫苗, 并检测其对斑点叉尾鲙的免疫效果。采用乳化法利用海藻酸钠-壳聚糖包被Srr蛋白, 测定其包封率、载药率及包被蛋白的抗原性; 通过拌饲投喂免疫斑点叉尾鲙, 分为Srr组、Srr微球组、空微球组以及对照组, 间接ELISA法检测免疫后斑点叉尾鲙的血清抗体水平, 试剂盒检测多项血清非特异性指标; 于免疫后第4周利用海豚链球菌攻毒, 计算各组相对保护率, 并通过实时荧光定量PCR检测相关基因的表达量。结果显示, 通过乳化法制得形态为圆形或椭圆形、大小较为均一的微球疫苗, 粒径为(4.26±1.13) μm, 包封率为92.38%, 载药率为19.41%, Western-blot分析表明Srr蛋白微球具有较好的抗原性; Srr微球组的抗体效价峰值出现在第4周, 明显高于其他组, 血清总蛋白、T-SOD以及溶菌酶活力均显著或极显著高于其他实验组, 并获得60%的相对保护率。荧光定量分析结果显示, Srr微球组攻毒后24h和48h各免疫基因表达量均有所上调。Srr蛋白微球疫苗能够提高斑点叉尾鲙抵抗海豚链球菌的能力, 对海豚链球菌起到了一定的预防作用。